Literature DB >> 12101187

Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance.

Yoshiaki Kido1, Jun Nakae, Marta Letizia Hribal, Shouhong Xuan, Argiris Efstratiadis, Domenico Accili.   

Abstract

Insulin and insulin-like growth factors (IGF) play overlapping and complementary roles in pancreatic beta-cell function and peripheral metabolism. In this study, we have analyzed mice bearing loss-of-function mutations of the insulin/IGF signaling systems. Combined inactivation of insulin receptor (Insr) and Igf1 receptor (Igf1r), but not of either receptor alone, resulted in a 90% decrease in the size of the exocrine pancreas, because of decreased cellular proliferation. In contrast to the findings in the exocrine compartment, endocrine alpha- and beta-cell development was unperturbed. Combined ablation of Igf1 and Igf2, the ligands for these two receptors, resulted in an identical phenotype. We also examined the effect of heterozygous null Igf1r mutations on glucose homeostasis in adult mice. Igf1r haploinsufficiency did not affect insulin action and compensatory beta-cell growth in insulin-resistant mice with combined Insr and Igf1r heterozygous null mutations, resulting in a considerably milder phenotype than combined haploinsufficiency for Insr and its main signaling substrates, Irs1 and Irs2. We conclude that Igf1r and Insr are required for embryonic development of the exocrine but not of the endocrine pancreas and that defects of Igf1r do not alter glucose homeostasis as long as the insulin receptor system remains intact.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101187     DOI: 10.1074/jbc.M206314200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Transcriptional networks controlling pancreatic development and beta cell function.

Authors:  J M Servitja; J Ferrer
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 2.  New insights into the integrated physiology of insulin action.

Authors:  Yukari Kitamura; Domenico Accili
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

Review 3.  Child health, developmental plasticity, and epigenetic programming.

Authors:  Z Hochberg; R Feil; M Constancia; M Fraga; C Junien; J-C Carel; P Boileau; Y Le Bouc; C L Deal; K Lillycrop; R Scharfmann; A Sheppard; M Skinner; M Szyf; R A Waterland; D J Waxman; E Whitelaw; K Ong; K Albertsson-Wikland
Journal:  Endocr Rev       Date:  2010-10-22       Impact factor: 19.871

4.  Pdk1 activity controls proliferation, survival, and growth of developing pancreatic cells.

Authors:  Joby J Westmoreland; Qian Wang; Mohamed Bouzaffour; Suzanne J Baker; Beatriz Sosa-Pineda
Journal:  Dev Biol       Date:  2009-07-25       Impact factor: 3.582

Review 5.  The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus.

Authors:  Venu Gopal Jonnalagadda; Allam Venkata Sita Ram Raju; Srinivas Pittala; Afsar Shaik; Nilakash Annaji Selkar
Journal:  Adv Pharm Bull       Date:  2014-02-07

6.  Reconstitution of insulin action in muscle, white adipose tissue, and brain of insulin receptor knock-out mice fails to rescue diabetes.

Authors:  Hua V Lin; Domenico Accili
Journal:  J Biol Chem       Date:  2011-01-14       Impact factor: 5.157

Review 7.  Growth factor control of pancreatic islet regeneration and function.

Authors:  Anke Assmann; Charlotte Hinault; Rohit N Kulkarni
Journal:  Pediatr Diabetes       Date:  2008-09-19       Impact factor: 4.866

8.  Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes.

Authors:  Bangyan L Stiles; Christine Kuralwalla-Martinez; Wei Guo; Caroline Gregorian; Ying Wang; Jide Tian; Mark A Magnuson; Hong Wu
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Irs2 inactivation suppresses tumor progression in Pten+/- mice.

Authors:  Matthias Szabolcs; Megan Keniry; Laura Simpson; Latarsha J Reid; Susan Koujak; Sarah C Schiff; Giselle Davidian; Scott Licata; Sofia Gruvberger-Saal; Vundavalli V V S Murty; Subhadra Nandula; Argiris Efstratiadis; Jake A Kushner; Morris F White; Ramon Parsons
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

10.  PBX1 is dispensable for neural commitment of RA-treated murine ES cells.

Authors:  Anne S Jürgens; Mateusz Kolanczyk; Dietrich C C Moebest; Tomasz Zemojtel; Urs Lichtenauer; Marlena Duchniewicz; Melanie P Gantert; Jochen Hecht; Uwe Hattenhorst; Stefan Burdach; Annette Dorn; Mark P Kamps; Felix Beuschlein; Daniel Räpple; Jürgen S Scheele
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-01-16       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.